AbbVie price target raised to $215 from $205 at Citi

Citi raised the firm’s price target on AbbVie (ABBV) to $215 from $205 and keeps a Buy rating on the shares. AbbVie repeated its usual beat in Q4, the analyst tells investors in a research note. The firm says AbbVie’s 2025 expected combined Skyrizi and Rinvoq revenues of $24B exceeds consensus and reaffirms the duo’s strength and ability in sunsetting Humira erosion concerns.